VHT — Vanguard Health Care ETF
Is VHT overbought or oversold? Here is the current MarketMoodz read.
Vanguard Health Care ETF (VHT) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The ETF name last closed at $345.56. The rating moved from Neutral to Overbought on November 13, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$345.56
- Last changeMoved from Neutral to Overbought on November 13, 2026
- SectorETF
See all overbought ETF stocks →
AI analysis
Vanguard Health Care ETF (VHT) offers diversified, liquid exposure to the healthcare sector with structural demand from aging populations and ongoing innovation in pharma, biotech and devices. The ETF benefits from Vanguard's low-cost structure and deep liquidity, making it a core sleeve for investors seeking defensive sector exposure. Near-term catalysts include tactical ETF flows driven by earnings momentum and policy headlines, while main vulnerabilities stem from regulatory reform risk, clinical/firm-specific headlines and episodic retail-driven volatility. Overall, the fund is positioned for moderate upside if sector sentiment remains constructive, but investors should expect periodic spikes in volatility tied to regulatory and trial news.
Key factors
- Broad exposure to pharmaceuticals, biotechnology, medical devices and healthcare services provides diversified, defensive sector exposure
- Large asset base and low expense ratio typical of Vanguard ETFs support liquidity and tax-efficient, cost-conscious ownership
- Aging demographics and secular trends in healthcare spending underpin steady long-term demand
- Tactical sector flows and recent market optimism around earnings momentum increase the likelihood of near-term inflows to healthcare-themed ETFs
- Innovation tailwinds (biotech pipelines, medical device adoption, AI-enabled drug discovery) offer upside catalysts
Risks
- Regulatory and policy risk (drug pricing reform, reimbursement changes, and affordability initiatives) that could pressure sector revenues
- Idiosyncratic headline risk from clinical trial failures, M&A outcomes or major litigation affecting large holdings and driving ETF volatility
- Retail-derivative-driven episodic volatility (0DTE/options, autocallables) that can amplify short-term price swings
- Concentration risk in large-cap pharma/biotech names can create outsized moves if a few constituents act negatively
- Macro-driven rotation out of defensive/healthcare exposures into growth or risk-on assets if sentiment shifts sharply
See today's live rating, score and targets
Members see the live hourly rating for VHT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.